Endovascular Today
VerifiedMagazine
Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurointerventionists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.
Endovascular Today is published 12 times per year and also offers a free biweekly eNewsletter, advising of recent FDA approvals, clinical trial updates, Medicare coverage news, and new product launches. Please visit our subscriptions page for more information on receiving Endovascular Today.
Actions
Media Outlet details
| Scope | Trade/B2B, Consumer |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
| Frequency | Monthly |
Recent Articles
Search ArticlesAngioDynamics Appoints Eric Honroth as President and Chief Executive Officer
KEY TAKEAWAYS Eric Honroth has been appointed President and Chief Executive Officer of AngioDynamics, effective November 2, 2026. Honroth will succeed Jim Clemmer, who will leave the board of directors and continue serving in a consulting capacity. Honroth brings more than 20 years of leadership experience in the medical device and life sciences industries, including roles at Getinge, Abbott Vascular, and Boston Scientific. October 9, 2026—AngioDynamics, Inc.
IDE Approved for Sonorous Neurovascular’s B-SILENT 2 Pivotal Trial for BosStent to Treat Pulsatile Tinnitus
KEY TAKEAWAYS The FDA approved an investigational device exemption for B-SILENT 2, a United States pivotal trial evaluating the BosStent for venous pulsatile tinnitus. Sonorous Neurovascular expects to initiate United States enrollment in the fourth quarter of 2026. The separate B-SILENT study is enrolling patients in France and Canada to support CE Mark certification of the device.
VEITHsymposium Names Dr. Gustavo Oderich as Executive Director and Future Chairman
KEY TAKEAWAYS Gustavo S. Oderich, MD, has been named Executive Director of VEITHsymposium and is committed to become Chairman of the meeting. Frank J. Veith, MD, announced the leadership transition as part of the organization’s plans for its long-term continuity. Enrico Ascher, MD, will remain Co-Chair of the annual meeting, and other VEITHsymposium team members will retain their current roles. October 9, 2027— Frank J. Veith, MD, Chairman of the VEITHsymposium, announced that Gustavo S.
B. Braun Medical to Close Interventional Systems Division
KEY TAKEAWAYS B. Braun plans to close its Interventional Systems division with commercial sales to continue through March 31, 2027. The division supplies devices used in interventional radiology, congenital and structural heart procedures, vascular surgery, and pulmonology. There are no immediate supply disruptions and the company plans to coordinate product distribution transitions with suppliers. October 9, 2026—B. Braun announced that it will wind down and close the B.
Okami Medical Receives Expanded Indication for LOBO Vascular Occluder
KEY TAKEAWAYS The FDA has expanded the indication for Okami Medical’s LOBO vascular occlusion system to include peripheral venous embolization. The expanded indication encompasses venous applications, including conditions such as pelvic venous disease and portal hypertension. The device incorporates HDBraid technology designed to support deliverability, vessel occlusion, and device stability.
Subgroup Analysis Presented From Reva’s MOTIV BTK Pivotal Trial
KEY TAKEAWAYS A subgroup analysis of the MOTIV BTK pivotal trial showed higher composite limb salvage and primary patency rates with the Motiv scaffold versus balloon angioplasty at 6 and 12 months. The analysis included patients with Rutherford class 4 and 5 chronic limb-threatening ischemia, with 69% of the 292 enrolled patients classified as Rutherford class 5.
AGILITY 9-Month Data Presented for BD’s Revello Vascular Covered Stent
KEY TAKEAWAYS The AGILITY iliac cohort met its primary composite safety and effectiveness endpoint, with a 2.8% failure rate compared with a 19% prespecified performance goal. At 9 months, the Revello vascular covered stent achieved 97.2% primary patency and 98.3% freedom from clinically driven target lesion revascularization. Revello received European CE Mark approval in March 2026 but remains investigational in the United States.
J&J’s Shockwave Peripheral IVL Evaluated at 24 Months in DISRUPT BTK II Postmarket Study
KEY TAKEAWAYS The DISRUPT PAD BTK II study evaluated 24-month outcomes of Shockwave IVL in patients with calcified BTK lesions, including those with CLTI. At 24 months, freedom from major target limb amputation was 94.8%, and freedom from clinically driven target lesion revascularization was 81%. VascuQoL scores improved significantly from baseline through 24 months (12.1 ± 4.0 to 18.3 ± 4.5; P < .001).
GREAT Pivotal Trial of Nipro’s Golazo Peripheral Atherectomy System Completes Enrollment
KEY TAKEAWAYS GREAT pivotal trial completed enrollment of 158 patients with symptomatic lower extremity PAD at United States centers. The study is evaluating Nipro’s investigational Golazo rotational atherectomy system under an FDA-approved investigational device exemption. Nipro plans to use the full-cohort endpoint analysis to support an FDA 510(k) submission, with United States commercial availability targeted for 2028.
Shape Memory’s Impede Embolization Plug Family Approved in Brazil
KEY TAKEAWAYS Brazil’s ANVISA authorizes Shape Memory Medical’s Impede, Impede-FX, and Impede-FX RapidFill embolization plugs. All three devices are indicated to obstruct or reduce blood flow in the peripheral vasculature in Brazil. Impede-FX RapidFill remains investigational in the United States, whereas Impede and Impede-FX are cleared for use. October 6, 2026—Shape Memory Medical Inc.